Marker Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
MRKR$0.99+10.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| | | | | | | |
|---|---|---|---|---|---|---|
| | For the Years Ended | |||||
| · · December 31, | ||||||
| | 2023 | 2022 | ||||
| Revenues: | | | | | | |
| Grant income | | $3,311,133 | | $3,513,544 | ||
| Total revenues | | 3,311,133 | | 3,513,544 | ||
| Operating expenses: | | | | | | |
| Research and development | | 10,416,789 | | 11,968,428 | ||
| General and administrative | | 7,475,722 | | 11,336,120 | ||
| Total operating expenses | | 17,892,511 | | 23,304,548 | ||
| Loss from operations | | (14,581,378) | | (19,791,004) | ||
| Other income (expenses): | | | ||||
| Arbitration settlement | | | — | | | (232,974) |
| Interest income | | 539,158 | | 248,063 | ||
| Loss from continuing operations before income taxes | | | (14,042,220) | | | (19,775,915) |
| Income tax expense | | | 3,675 | | | — |
| Net loss from continuing operations | | | (14,045,895) | | | (19,775,915) |
| | | | | | | |
| Discontinued operations: | | | | | | |
| Loss from discontinued operations | | | (2,922,406) | | | (10,154,779) |
| Gain on disposal of discontinued operations, net of $63,000 in tax | | | 8,731,487 | | | — |
| Income (loss) from discontinued operations | | | 5,809,081 | | | (10,154,779) |
| Net loss | | $(8,236,814) | | $(29,930,694) | ||
| | | | | | | |
| Net earnings (loss) per share: | | | | | | |
| Loss from continuing operations, basic and diluted | | $(1.59) | | $(2.37) | ||
| Income (loss) from discontinued operations, basic and diluted | | $0.66 | | $(1.22) | ||
| Net loss per share, basic and diluted | | $(0.94) | | $(3.58) | ||
| | | | | | ||
| Weighted average number of common shares outstanding: | | | | | | |
| Basic | | | 8,809,382 | | | 8,351,003 |
| Diluted | | | 8,809,382 | | | 8,351,003 |
On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock. All historical share and per share amounts reflected in this report have been adjusted to reflect the reverse stock split.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.